|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Synthetic peptide corresponding to residues D(985) V V D A D E Y L I P Q(996) of human EGFR.|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay dependent|
|Immunoprecipitation (IP)||Assay dependent|
|Radioimmune Assays (RIA)||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-24226 detects both phosphorylated and un-phosphorylated EGFR in human samples. This antibody does not cross react with mouse or rat EGFR, or with ERbB2, ERbB3, or ERbB4.
MA1-24226 has been successfully used in ELISA, Radioimmune assays, immunohistochemistry (paraffin and frozen) and immunoprecipitation procedures.
The MA1-24226 immunogen is a synthetic peptide corresponding to residues D(985) V V D A D E Y L I P Q(996) of human EGFR.
Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze-thaw cycles.
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Identification of tumor epithelium and stroma in tissue microarrays using texture analysis.
MA1-24226 was used in immunohistochemistry to study the use of texture analysis for the automated identification of epithelium and stroma in tumor tissue microarrays
|Linder N,Konsti J,Turkki R,Rahtu E,Lundin M,Nordling S,Haglund C,Ahonen T,Pietikäinen M,Lundin J||Diagnostic pathology (7:null)||2012|
Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization.
MA1-24226 was used in immunohistochemistry to study AR, EGFR, and HER2 protein expresion and whether the EGFR and HER2 genes are amplified in prostate cancer
|Baek KH,Hong ME,Jung YY,Lee CH,Lee TJ,Park ES,Kim MK,Yoo JH,Lee SW||Cancer research and treatment : official journal of Korean Cancer Association (44:50)||2012|
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
MA1-24226 was used in immunohistochemistry to identify the targets of miR-34a microRNA in human breast cancer
|Mackiewicz M,Huppi K,Pitt JJ,Dorsey TH,Ambs S,Caplen NJ||Breast cancer research and treatment (130:663)||2011|
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
MA1-24226 was used in immunohistochemistry to investigate the prognostic significance of inducible nitric oxide synthase in estrogen receptor-negative breast cancer
|Glynn SA,Boersma BJ,Dorsey TH,Yi M,Yfantis HG,Ridnour LA,Martin DN,Switzer CH,Hudson RS,Wink DA,Lee DH,Stephens RM,Ambs S||The Journal of clinical investigation (120:3843)||2010|
Antigen expression of human eccrine sweat glands.
MA1-24226 was used in immunohistochemistry to identify the phenotypic markers of human eccrine sweat glands
|Li HH,Zhou G,Fu XB,Zhang L||Journal of cutaneous pathology (36:318)||2009|
Differences in the tumor microenvironment between African-American and European-American breast cancer patients.
MA1-24226 was used in immunohistochemistry to compare tumor microenvironments between African-American and European-American breast cancer patients
|Martin DN,Boersma BJ,Yi M,Reimers M,Howe TM,Yfantis HG,Tsai YC,Williams EH,Lee DH,Stephens RM,Weissman AM,Ambs S||PloS one (4:null)||2009|
Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion.
MA1-24226 was used in immunohistochemistry to characterise a new Ewing's sarcoma cell line derived from a malignant pleural effusion
|Schiavo R,Tullio C,La Grotteria M,Andreotti IC,Scarpati B,Romiti L,Bozzi F,Pedrazzoli P,Siena S||Anticancer research (27:3273)||2007|
Higher expression of epidermal growth factor receptor is associated with extracellular matrix metalloprotease inducer in colorectal adenocarcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters.
MA1-24226 was used in immunohistochemistry to investigate the expression of epidermal growth factor receptor and extracellular matrix metalloprotease inducer in colorectal cancers
|Jin JS,Wu CY,Lin YF,Wang JY,Yu CP,Sheu LF,Chiang H,Tsai WC,Lee WH||Disease markers (22:309)||2007|
Tyrosine phosphorylation controls PCNA function through protein stability.
MA1-24226 was used in immunohistochemistry to study the role of protein phosphorylation in controlling proliferating cell nuclear antigen function
|Wang SC,Nakajima Y,Yu YL,Xia W,Chen CT,Yang CC,McIntush EW,Li LY,Hawke DH,Kobayashi R,Hung MC||Nature cell biology (8:1359)||2006|
Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations--a study of 32 cases.
MA1-24226 was used in immunohistochemistry to investigate the clinicopathological features of gemistocytic astrocytomas
|Avninder S,Sharma MC,Deb P,Mehta VS,Karak AK,Mahapatra AK,Sarkar C||Journal of neuro-oncology (78:123)||2006|
Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK.
MA1-24226 was used in immunohistochemistry to study the interaction of hepatocyte growth factor-regulated tyrosine kinase substrate with PELP1 and its role in MAPK activation
|Rayala SK,Hollander Pd,Balasenthil S,Molli PR,Bean AJ,Vadlamudi RK,Wang RA,Kumar R||The Journal of biological chemistry (281:4395)||2006|
Changes in the expression and cytological localization of betacellulin and its receptors (ErbB-1 and ErbB-4) in the trophoblasts in human placenta over the course of pregnancy.
MA1-24226 was used in immunohistochemistry to study the expression of betacellulin and its receptors in trophoblasts in human placenta over the course of pregnancy
|Tanimura K,Nakago S,Murakoshi H,Takekida S,Moriyama T,Matsuo H,Hashimoto K,Maruo T||European journal of endocrinology (151:93)||2004|
Characterization of putative stem cell phenotype in human limbal epithelia.
MA1-24226 was used in immunohistochemistry to evaluate the stem cell molecular markers in human limbal epithelia
|Chen Z,de Paiva CS,Luo L,Kretzer FL,Pflugfelder SC,Li DQ||Stem cells (Dayton, Ohio) (22:355)||2004|
|Not Applicable||Not Cited||
Sulindac metabolites inhibit epidermal growth factor receptor activation and expression.
MA1-24226 was used in western blot to test if sulindac metabolites block activation or expression of the epidermal growth factor receptor
|Pangburn HA,Kraus H,Ahnen DJ,Rice PL||Journal of carcinogenesis (4:null)||2005|
Expression of serum human leukocyte antigen and growth factor levels in a Greek family with familial endometriosis.
MA1-24226 was used in ELISA to study the levels of serum leukocyte antigen and VEGF in a family with familial endometriosis
|Matalliotakis IM,Goumenou AG,Koumantakis GE,Athanassakis I,Dionyssopoulou E,Neonaki MA,Vassiliadis S||Journal of the Society for Gynecologic Investigation (10:118)||2003|
Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines.
MA1-24226 was used in ELISA to study the effect of anti-endometriosis medicines on serum growth factor levels in women with endometriosis
|Matalliotakis IM,Goumenou AG,Koumantakis GE,Neonaki MA,Koumantakis EE,Dionyssopoulou E,Athanassakis I,Vassiliadis S||International immunopharmacology (3:81)||2003|